好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cognitive sequelae in MOG antibody-associated disease
Autoimmune Neurology
P13 - Poster Session 13 (8:00 AM-9:00 AM)
6-025

To assess the cognitive sequelae of patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

MOGAD is a recently recognized CNS demyelinating disease that frequently leads to encephalitis. There is very little information on the cognitive sequelae in MOGAD.

We identified 9 patients with MOGAD who underwent neuropsychological testing. Clinical information and neuropsychological assessments were analyzed via retrospective chart review.

The median age of this cohort was 33 years (17-65 years), among which 33% were female. MOG antibody titers ranged from 1:40 to 1:1000. Prior attacks of encephalitis had occurred in 8 of 9 (89%) patients. Seven (78%) had memory complaints and 2 (22%) had seizures. Of the 8 with prior cerebral attacks, the median time from the last cerebral attack to neuropsychological assessment was 147 days (range, 70-244 days). At the time of cognitive assessment, the median Expanded Disability Status Scale (EDSS) was 3 (range, 1-5.5) and the median Modified Rankins Scale (mRS) was 2 (range, 1-3). On neuropsychological assessment, impairment was classified as scores falling below the 5th percentile of normative standards.  Deficits were observed in multiple domains, including verbal list learning, 1/8 (13%); list delayed recall 2/8 (25%); story learning, 1/8 (13%); short learning delayed recall, 2/8 (25%); visual learning, 2/7 (29%); visual delayed recall, 1/7 (14%); confrontation naming, 2/8 (25%); lexical fluency, 4/9 (44%); semantic fluency, 3/9 (33%); visuospatial perception, 2/7 (29%); auditory working memory 1/7 (15%); visual attention/ processing speed, 1/6(17%); set-shifting, 2/9 (22%) and concept formation, 2/7(29%). Collectively, 4/9 (44%) of the sample achieved impaired performance in one or more domains.

Up to 44% of this clinically referred MOGAD sample displayed salient cognitive impairment, most often in new-learning and executive function.  Such impairment could impact activities of daily living, ability to retain employment and impair learning in school aged children.

Authors/Disclosures
Xiaoyang Li, MD
PRESENTER
Dr. Li has nothing to disclose.
No disclosure on file
John Chen John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. John Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB.
Jan-Mendelt Tillema, MD (Mayo Clinic) Dr. Tillema has nothing to disclose.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Merck. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology that is relevant to AAN interests or activities.